Tags

Type your tag names separated by a space and hit enter

Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Eur Rev Med Pharmacol Sci. 2020 05; 24(9):5062-5070.ER

Abstract

OBJECTIVE

To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.

PATIENTS AND METHODS

Altogether 100 patients with preeclampsia admitted to the Children & Women's Healthcare of Laiwu City were selected. They were divided into control group and experimental group according to different treatment methods. Among them, 51 patients in the control group were treated with magnesium sulfate combined with nifedipine, and 49 patients in the experimental group were treated with labetalol on the basis of the treatment in the control group. The therapeutic effects of the two methods were compared. The levels of the following factors in the two groups were compared: kallikrein expression, pregnancy-associated plasma protein A (PAPP-A), pregnancy-specific β1 glycoprotein (SPI), placental growth factor (PLGF), human placental prolactin (HPL), transforming growth factor β1(TGF-β1), vascular cell adhesion molecule 1 (VCAM-1) and E-selectin in serum and placenta tissues.

RESULTS

After treatment, the blood pressure in the experimental group was lower than that in the control group (p<0.05). The expression of kallikrein in serum and placental tissue of the patients in the experimental group was higher than that of the patients in the control group (p<0.05); PAPP-A level was lower than that in the control group (p<0.05); TGF-β1 level was higher than that in the control group (p<0.05); VCAM-1 and E-selectin were lower than those in the control group (p<0.05), and kallikrein and TGF-β1 in serum and placenta in the non-occurrence group were higher than those in the occurrence group (p<0.05). The serum and placenta PAPP-A, VCAM-1, and E-selectin in the non-occurrence group were lower than those in the occurrence group (p<0.05).

CONCLUSIONS

Magnesium sulfate combined with nifedipine and labetalol has good efficacy in the treatment of preeclampsia. They can promote the expression of endogenous kallikrein, reduce the level of pregnancy-related hypertension predictors, and weaken the infiltration ability of cytotrophoblasts.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Wu Y
Department of Obstetrics, The Children & Women's Healthcare of Laiwu City, Laiwu, P.R. China. rn72c7@163.com.
Wang DJ
No affiliation info available
Zhang Y
No affiliation info available
Zhang YX
No affiliation info available
Zhang R
No affiliation info available

MeSH

Administration, OralAdultE-SelectinFemaleHumansLabetalolMagnesium SulfateNifedipinePre-EclampsiaPregnancyProspective StudiesTransforming Growth Factor beta1Vascular Cell Adhesion Molecule-1Young Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32432770

Citation

Wu, Y, et al. "Regulation of Magnesium Sulfate Combined With Nifedipine and Labetalol On Disease-related Molecules in Serum and Placenta in the Treatment of Preeclampsia." European Review for Medical and Pharmacological Sciences, vol. 24, no. 9, 2020, pp. 5062-5070.
Wu Y, Wang DJ, Zhang Y, et al. Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. Eur Rev Med Pharmacol Sci. 2020;24(9):5062-5070.
Wu, Y., Wang, D. J., Zhang, Y., Zhang, Y. X., & Zhang, R. (2020). Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. European Review for Medical and Pharmacological Sciences, 24(9), 5062-5070. https://doi.org/10.26355/eurrev_202005_21199
Wu Y, et al. Regulation of Magnesium Sulfate Combined With Nifedipine and Labetalol On Disease-related Molecules in Serum and Placenta in the Treatment of Preeclampsia. Eur Rev Med Pharmacol Sci. 2020;24(9):5062-5070. PubMed PMID: 32432770.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. AU - Wu,Y, AU - Wang,D-J, AU - Zhang,Y, AU - Zhang,Y-X, AU - Zhang,R, PY - 2020/5/21/entrez PY - 2020/5/21/pubmed PY - 2021/4/1/medline SP - 5062 EP - 5070 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 24 IS - 9 N2 - OBJECTIVE: To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. PATIENTS AND METHODS: Altogether 100 patients with preeclampsia admitted to the Children & Women's Healthcare of Laiwu City were selected. They were divided into control group and experimental group according to different treatment methods. Among them, 51 patients in the control group were treated with magnesium sulfate combined with nifedipine, and 49 patients in the experimental group were treated with labetalol on the basis of the treatment in the control group. The therapeutic effects of the two methods were compared. The levels of the following factors in the two groups were compared: kallikrein expression, pregnancy-associated plasma protein A (PAPP-A), pregnancy-specific β1 glycoprotein (SPI), placental growth factor (PLGF), human placental prolactin (HPL), transforming growth factor β1(TGF-β1), vascular cell adhesion molecule 1 (VCAM-1) and E-selectin in serum and placenta tissues. RESULTS: After treatment, the blood pressure in the experimental group was lower than that in the control group (p<0.05). The expression of kallikrein in serum and placental tissue of the patients in the experimental group was higher than that of the patients in the control group (p<0.05); PAPP-A level was lower than that in the control group (p<0.05); TGF-β1 level was higher than that in the control group (p<0.05); VCAM-1 and E-selectin were lower than those in the control group (p<0.05), and kallikrein and TGF-β1 in serum and placenta in the non-occurrence group were higher than those in the occurrence group (p<0.05). The serum and placenta PAPP-A, VCAM-1, and E-selectin in the non-occurrence group were lower than those in the occurrence group (p<0.05). CONCLUSIONS: Magnesium sulfate combined with nifedipine and labetalol has good efficacy in the treatment of preeclampsia. They can promote the expression of endogenous kallikrein, reduce the level of pregnancy-related hypertension predictors, and weaken the infiltration ability of cytotrophoblasts. SN - 2284-0729 UR - https://www.unboundmedicine.com/medline/citation/32432770/Regulation_of_magnesium_sulfate_combined_with_nifedipine_and_labetalol_on_disease_related_molecules_in_serum_and_placenta_in_the_treatment_of_preeclampsia_ DB - PRIME DP - Unbound Medicine ER -